Waltering Kati K, Helenius Merja A, Sahu Biswajyoti, Manni Visa, Linja Marika J, Jänne Olli A, Visakorpi Tapio
Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, Tampere, Finland.
Cancer Res. 2009 Oct 15;69(20):8141-9. doi: 10.1158/0008-5472.CAN-09-0919. Epub 2009 Oct 6.
Androgen receptor (AR) is known to be overexpressed in castration-resistant prostate cancer. To interrogate the functional significance of the AR level, we established two LNCaP cell sublines expressing in a stable fashion two to four times (LNCaP-ARmo) and four to six times (LNCaP-ARhi) higher level of AR than the parental cell line expressing the empty vector (LNCaP-pcDNA3.1). LNCaP-ARhi cell line grew faster than the control line in low concentrations, especially in 1 nmol/L 5alpha-dihydrotestosterone (DHT). Microarray-based transcript profiling and subsequent unsupervised hierarchical clustering showed that LNCaP-ARhi cells clustered together with VCaP cells, containing endogenous AR gene amplification and overexpression, indicating the central role of AR in the overall regulation of gene expression in prostate cancer cells. Two hundred forty genes showed >2-fold changes on DHT treatment in LNCaP-ARhi at 4 h time point, whereas only 164 and 52 showed changes in LNCaP-ARmo and LNCaP-pcDNA3.1, respectively. Many androgen-regulated genes were upregulated in LNCaP-ARhi at 10-fold lower concentration of DHT than in control cells. DHT (1 nmol/L) increased expression of several cell cycle-associated genes in LNCaP-ARhi cells. ChIP-on-chip assay revealed the presence of chromatin binding sites for AR within +/-200 kb of most of these genes. The growth of LNCaP-ARhi cells was also highly sensitive to cyclin-dependent kinase inhibitor, roscovitine, at 1nmol/L DHT. In conclusion, our results show that overexpression of AR sensitizes castration-resistant prostate cancer cells to the low levels of androgens. The activity of AR signaling pathway is regulated by the levels of both ligand and the receptor.
已知雄激素受体(AR)在去势抵抗性前列腺癌中过表达。为了探究AR水平的功能意义,我们建立了两个LNCaP细胞亚系,它们稳定表达的AR水平比表达空载体的亲本细胞系(LNCaP-pcDNA3.1)高2至4倍(LNCaP-ARmo)和4至6倍(LNCaP-ARhi)。LNCaP-ARhi细胞系在低浓度下,尤其是在1 nmol/L 5α-二氢睾酮(DHT)中,比对照细胞系生长更快。基于微阵列的转录谱分析和随后的无监督层次聚类显示,LNCaP-ARhi细胞与含有内源性AR基因扩增和过表达的VCaP细胞聚集在一起,表明AR在前列腺癌细胞基因表达的整体调控中起核心作用。在4小时时间点,240个基因在LNCaP-ARhi细胞中经DHT处理后显示出>2倍的变化,而在LNCaP-ARmo和LNCaP-pcDNA3.1中分别只有164个和52个基因显示出变化。许多雄激素调节基因在LNCaP-ARhi细胞中在比对照细胞低10倍的DHT浓度下就被上调。DHT(1 nmol/L)增加了LNCaP-ARhi细胞中几个细胞周期相关基因的表达。芯片上的染色质免疫沉淀分析揭示了这些基因大多数在+/-200 kb范围内存在AR的染色质结合位点。在1 nmol/L DHT时,LNCaP-ARhi细胞的生长对细胞周期蛋白依赖性激酶抑制剂roscovitine也高度敏感。总之,我们的结果表明,AR的过表达使去势抵抗性前列腺癌细胞对低水平雄激素敏感。AR信号通路的活性受配体和受体水平的调节。